Marinus Pharmaceuticals Cuts 45% of Workforce Following Clinical Setbacks

Layoff Percentage:
Marinus Pharmaceuticals is laying off 45% of its employees as part of cost-cutting measures following disappointing Phase III trials of ganaxolone for treating seizures associated with tuberous sclerosis complex (TSC)134.

Clinical Development:
The company is discontinuing further clinical development of ganaxolone and exploring strategic alternatives to maximize value for stockholders23.

Previous Layoffs:
This is not the first workforce reduction for Marinus; in May, the company announced a 20% workforce reduction as part of earlier cost-cutting measures2.

Future Plans:
Marinus is considering a potential expansion opportunity for refractory status epilepticus (RSE) with its reduced workforce4.

Employee Count:
As of December 31, Marinus had 165 full-time employees, but this number is likely lower due to previous layoffs and the current 45% reduction2.

Sources:

1. https://www.biospace.com/job-trends/marinus-pharmaceuticals-lays-off-45-of-employees

2. https://www.biospace.com/biospace-layoff-tracker

3. https://www.fiercepharma.com/pharma/marinus-lops-45-staff-seizure-med-ztalmy-remains-limbo-following-phase-3-misses

4. https://www.cafepharma.com/content/marinus-cuts-45-staff-after-key-medicine-stumbled-pair-phase-3-trials